Parkwood LLC Biomarin Pharmaceutical Inc Transaction History

Parkwood LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $167,836 - $216,919	2,202 New	2,202 $212,000
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $87,476 - $116,918	-997 Reduced 21.88%	3,560 $346,000
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $78,663 - $105,588	972 Added 27.11%	4,557 $472,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $38,450 - $45,367	468 Added 15.01%	3,585 $304,000
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $27,734 - $33,697	-388 Reduced 11.07%	3,117 $3,000
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $16,713 - $20,855	-225 Reduced 6.03%	3,505 $270,000
Q4 2021 Feb 11, 2022	SELL	$71.72 - $91.47 $20,009 - $25,520	-279 Reduced 6.96%	3,730 $330,000
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $41,945 - $47,948	561 Added 16.27%	4,009 $310,000
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $83,816 - $94,116	-1,110 Reduced 24.35%	3,448 $288,000
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $118,970 - $144,378	-1,592 Reduced 25.89%	4,558 $344,000
Q4 2020 Feb 12, 2021	BUY	$72.61 - $90.2 $446,551 - $554,730	6,150 New	6,150 $539,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

Stay updated on Parkwood LLC with notifications on news.